Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,701–7,800 of 15,747
Vega‐Magaña, N., Muñóz-Valle, J. F., Rodríguez, M. P., Segura, O. V., Pereira-Suárez, A. L., Hernández‐Bello, J., & García‐Chagollán, M. (2022) · Vaccines · doi:10.3390/vaccines10071117 · Cited by 9
“When vaccine efficacy was evaluated in clinical trials, they excluded individuals with a prior diagnosis of COVID-19 [6,25]; therefore, little is known about how mRNA vaccine responses behave following a previous natural infection.”
BackgroundRahman, M. S., Harun, M. G. D., Sumon, S. A., Mohona, T. M., Abdullah, S. A. H. M., Khan, M. N. H., Gazi, M. I., Islam, M. S., & Anwar, M. M. U. (2022) · Vaccines · doi:10.3390/vaccines10121987 · Cited by 11
“Evidence showed that vaccines significantly reduced the infection, severity, and mortality across a wide age range of populations in developed and developing countries [13,16].”
BackgroundHernández, A., Boigués, M., Felip, E., Cucurull, M., Notario, L., Pous, A., Torres, P., Benitez, M., Rodríguez, M., Quirant‐Sánchez, B., et al. (2022) · Cancers · doi:10.3390/cancers15010137 · Cited by 9
To, A., Wong, T. A. S., Lieberman, M. M., Thompson, K. S., Ball, A. H., Pessaint, L., Greenhouse, J. J., Daham, N., Cook, A., Narvaez, B., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00600 · Cited by 10
Şancı, E., Kocaeli-Turkey, Örçen, C., et al. (2021) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2021.1212 · Cited by 8
Emerging trends of research on mRNA vaccines: A co-citation analysis
Chen, J., Zhang, T., Lu, Y. Z., Yang, X., & Ouyang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2110409 · Cited by 11
“Shortly afterward, a pivotal trial showing the 95% efficacy of two-dose regimen of BNT162b2 in preventing COVID-19 in persons aged ≥16 was published.(59) Nearly synchronously, in late 2020, a phase 1 study of mRNA-1273 supporting the further development of this vaccine was published.”
BackgroundTani, N., Ikematsu, H., Watanabe, H., Goto, T., Yanagihara, Y., Kurata, Y., Harada, Y., Horiuchi, T., Akashi, K., Shimono, N., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100489 · Cited by 9
“The mRNA-based COVID-19 vaccine developed by BioNTech and Pfizer (BNT162b2) has initially demonstrated an efficacy of 95 % in preventing symptomatic COVID-19 [1] and exhibited strong immunogenicity, evidenced by robust specific antibody responses [2,3].”
BackgroundEvaluation of Israeli healthcare workers knowledge and attitudes toward the COVID‐19 vaccine
Zaitoon, H., Sharkansky, L., Ganaim, L., et al. (2021) · Public Health Nursing · doi:10.1111/phn.12987 · Cited by 8
Chou, S., Chang, Y., Liao, C., Chen, T., Sun, K.-J., Huang, W., & Wu, Y. (2022) · Platelets · doi:10.1080/09537104.2022.2042237 · Cited by 8
Wolszczak-Biedrzycka, B., Bieńkowska, A., Smolińska-Fijołek, E., Biedrzycki, G., & Dorf, J. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s390351 · Cited by 8
“The ECLIA test is a three-step procedure that uses a recombinant protein representing the receptor binding domain (RBD) of the S antigen in a double-antigen assay format and favors the detection of high-affinity antibodies against SARS-CoV-2.”
BackgroundInfluentialThe Impact of Risk Compensation Adaptive Behavior on the Final Epidemic Size
Espinoza, B., Chen, J., Orr, M., Saad-Roy, C. M., Levin, S. A., & MARATHE, M. V. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109370 · Cited by 9
The Role of Rilonacept in Recurrent Pericarditis
Presti, S. L., Elajami, T. K., Reyaldeen, R. M., Anthony, C. M., & Klein, A. L. (2021) · Heart International · doi:10.17925/hi.2021.15.1.20 · Cited by 8
Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
Kim, S., & Seok, H. Y. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06676-1 · Cited by 10
“While it is unsatisfactory for reported vaccine efficacy in previous phase 3 clinical trials [2, 41], we assumed that these breakthrough infections also occurred in part by reduced immunogenicity and, more importantly, because of the spread of the omicron variant in South Korea.”
BackgroundDemoulin, N., Scohy, A., Gillion, V., Godefroid, N., Jadoul, M. Y., & Morelle, J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab102 · Cited by 9
Henig, I. J., Isenberg, J., Yehudai‐Ofir, D., Leiba, R., Ringelstein‐Harlev, S., Ram, R., Avni, B. R., Amit, O., Grisariu, S., Azoulay, T., et al. (2023) · Vaccines · doi:10.3390/vaccines11040775 · Cited by 8
“1%) of patients with hematological malignancies [8,9].”
BackgroundMinciullo, P. L., Amato, G., Vita, F., et al. (2023) · Vaccines · doi:10.3390/vaccines11020322 · Cited by 8
“Clinical trials reported that the Pfizer/BioNTech (BNT162b2) mRNA vaccine had a 95% efficacy [3] and the Moderna mRNA vaccine (mRNA1273) had a 94.”
BackgroundEvaluating vaccine allocation strategies using simulation-assisted causal modeling
Kekić, A., Dehning, J., Gresele, L., von Kügelgen, J., Priesemann, V., & Schölkopf, B. (2023) · Patterns · doi:10.1016/j.patter.2023.100739 · Cited by 11
“The gold standard for inferring average causal effects are randomized controlled trials (RCTs),(10) which are used to evaluate medical treatments such as COVID-19 vaccines.(11) However, to compare full vaccine allocation strategies at the country level, running an RCT is infeasible in practice (there is only one copy…”
Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients
Mohanraj, D., Baldwin, S., Singh, S., Gordon, A., & Whitelegg, A. M. E. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104501 · Cited by 10
Adapting French COVID-19 vaccination campaign duration to variant disseminationPreprint
Pageaud, S., Ponthus, N., Gauchon, R., Pothier, C., Rigotti, C., Eyraud-Loisel, A., Bertoglio, J. P., Bienvenüe, A., Gueyffier, F., Vanhems, P., et al. (2021) · medRxiv · doi:10.1101/2021.03.17.21253739 · Cited by 9
HIV infection and the implication for COVID‐19 vaccination
Oyelade, T., Raya, R. P., & Latief, K. (2022) · Public Health Challenges · doi:10.1002/puh2.14 · Cited by 6
A Case of Recurrent Acute Anterior Uveitis After the Administration of COVID-19 Vaccine
Alhamazani, M. A., Alruwaili, W. S., Alshammri, B., et al. (2022) · Cureus · doi:10.7759/cureus.22911 · Cited by 8
“The safety profile of this vaccine appears to be similar to that of other viral vaccines, with mild to severe pain, swelling, redness at the injection site, chills, fatigue, and headache being the most common side effects [4].”
BackgroundCancer management during the COVID-19 world pandemic
Sobhani, N., Mondani, G., Roviello, G., Catalano, M., Sirico, M., D’Angelo, A., Scaggiante, B., & Generali, D. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03524-1 · Cited by 9
Jang, W., Kim, B., Kim, E. S., Song, K., Moon, S. M., Lee, M. J., Park, J. Y., Kim, J., Shin, M. J., Lee, H., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e343 · Cited by 7
Yang, M. M., Taylor, K. E., Paez, D., Carividi, A., Demissie, E., Pawar, N., El‐Qunni, A. A., McMorrow, L. E., Schriefer, R. E., Huang, K., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24894 · Cited by 9
Saba, A. A., Adiba, M., Chakraborty, S., & Nabi, A. N. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0130 · Cited by 9
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein
Bordoloi, D., Xu, Z., Ho, M., Purwar, M., Bhojnagarwala, P. S., Cassel, J. A., Giron, L. B., Walker, S. N., Kulkarni, A. J., Tello‐Ruiz, E., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00058 · Cited by 8
“68,69 Furthermore, a single dose of Ad26.”
Enfermedad por coronavirus 2019 (COVID-19)
Ochoa, J. E. S., & Cueto, M. C. S. (2021) · Medicina UPB · doi:10.18566/medupb.v40n2.a06 · Cited by 13
Ghosh, S., Oliva, A. O., Ghosh, A., Banerjee, M., & Seshaiyer, P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290368 · Cited by 10
Glasser, J. W., Feng, Z., Vo, M., Jones, J. N., & Clarke, K. E. N. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111296 · Cited by 8
“(2021), the lower of the two mRNA vaccines authorized for use at the time (Polack et al., 2020), it fits the prevalence of anti-N or anti-S among blood donors on 4 April 2021 less well (Fig.”
BackgroundKoseki, T., Teramachi, M., Koga, M., Ko, M. S. H., Amano, T., Yu, H., Amano, M., Leyder, E. C., Badiola, M., Ray, P., et al. (2023) · Vaccines · doi:10.3390/vaccines11121767 · Cited by 9
(2021) · doi:10.1101/2021.08.30.21262862 · Cited by 8
“between obese and non-obese vaccine recipients [3].”
BackgroundKanokudom, S., Chansaenroj, J., Suntronwong, N., Assawakosri, S., Yorsaeng, R., Nilyanimit, P., Aeemjinda, R., Khanarat, N., Vichaiwattana, P., Klinfueng, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11030570 · Cited by 8
“, New York City, NY, USA) vaccine contains 30 μg of mRNA encoding the SARS-CoV-2 spike protein (S) [22].”
BackgroundSeely, D., Legacy, M., Conte, E., Keates, C., Psihogios, A., Ramsay, T., Fergusson, D. A., Kanji, S., Simmons, J.-G., & Wilson, K. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073761 · Cited by 9
Fernandes-Matano, L., Salas-Lais, Á. G., Grajales-Muñíz, C., Hernández‐Ávila, M., Garfias, Y., Rodríguez-Sepúlveda, M. C., Segura-Sánchez, C., Montes-Herrera, D., Mendoza-Sánchez, D., Ángeles-Martínez, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02376-22 · Cited by 8
“The vaccines are delivered using various platforms (5), such as mRNA (6, 7), nonreplicative adenovirus vectors (8, 9), and inactivated viruses (10).”
BackgroundKim, S., Bea, S., Choe, S., Choi, N., & Shin, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03618-w · Cited by 11
“…number of drugs reported concurrently, as documented in AEFI related to autoimmune disorders reports associated with COVID-19 vaccines Co-reported AEs with COVID-19 vaccines include musculoskeletal and connective tissue disorders such as arthralgia, myalgia, and nervous system disorders [34–36].”
Gupta, D., Ahmed, F., Tandel, D., Parthasarathy, H., Vedagiri, D., Sah, V., Mohan, B. K., Khan, R. A., Kondiparthi, C., Savari, P., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108981 · Cited by 9
TONG, J. J., Zhu, C., Lai, H., Feng, C., & Zhou, D. (2021) · Vaccines · doi:10.3390/vaccines9030296 · Cited by 9
Ye, C., Qi, L., Ji, W., & Zheng, S. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.606755 · Cited by 11
Horiuchi, H., Sasaki, H., Miyazaki, K., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.11.018 · Cited by 8
“The presence of neutralizing antibody is thought to be essential for preventing COVID-19, given that COVID-19 vaccines have been shown to be effective at preventing the disease [2].”
Iryaningrum, M. R., Cahyadi, A., Damara, F. A., Bandiara, R., & Marbun, M. B. H. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.13 · Cited by 9
“Trials have been conducted to evaluate the vaccine’s safety and efficacy and yet, KTRs were mostly excluded from the analysis [5,6].”
Masetti, M., Scuppa, M. F., Aloisio, A., Giovannini, L., Borgese, L., Manno, S. B., Tazza, B., Pascale, R., Bonazzetti, C., Caroccia, N., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11030755 · Cited by 9
“Because the immune protection from mRNA vaccines has been reported to be effective after at least two weeks following vaccine administration [11,12], patient follow-up started two weeks after the last vaccine dose.”
BackgroundCOVID-19 vaccination for patients with primary immunodeficiency
Roifman, C. M., & Vong, L. (2021) · LymphoSign Journal · doi:10.14785/lymphosign-2021-0020 · Cited by 9
Alleman, T. W., Rollier, M., Vergeynst, J., & Baetens, J. M. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.06.027 · Cited by 10
“Vaccination has the explicit goal of reducing viral transmission and/or disease severity and has been shown to do this in both clinical trials [17] and society-scale follow-up studies [18].”
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context
Ruschig, M., & Marschall, A. L. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00580-y · Cited by 10
Molecular epidemiological analysis of SARS-CoV-2 genovariants in Moscow and Moscow region
Никитична, О. Е., Евгеньевна, С. Т., Prilipov, A. G., Tikhomirov, E. E., Larichev, V. F., Sayfullin, М. А., & Гребенникова, Т. В. (2022) · Problems of Virology · doi:10.36233/0507-4088-146 · Cited by 8
SARS-COV-2 vaccine responses in renal patient populations
Smith, R., Cooper, D. J., Döffinger, R., Stacey, H., Al-Mohammad, A., Goodfellow, I., Baker, S. G., Lear, S. E., Hosmillo, M. D. T., Pritchard, N. R., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02792-w · Cited by 10
Self-citationCOVID-19-induced liver injury in infants, children, and adolescents
Bitar, R., Elghoudi, A., Rawat, D. J., Azaz, A., Miqdady, M. S., & Narchı, H. (2023) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v12.i3.57 · Cited by 9
Mutant strains of SARS-CoV-2 are more prone to infect obese patient: a review
Ningombam, S. S., Kumar, R., & Tanwar, P. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01819-w · Cited by 8
Hannawi, S., Wu, X.-H., Villalobos, R. E., Burhan, E., Lallaine Borra, M. D., Gupta, R. K., Aquitania, G. P., Ang, B. W. C., Mae A. Zabat, G., Roa, C. C., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.013 · Cited by 8
Kitro, A., Sirikul, W., Thongkum, W., Soponpong, S., Yasamut, U., Kiratipaisarl, W., Kosai, A., Kasinrerk, W., Tayapiwatana, C., & Srithanaviboonchai, K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.020 · Cited by 8
Takizawa, T., Ihara, K., Uno, S., Ohtani, S., Watanabe, N., Imai, N., Nakahara, J., Hori, S., García‐Azorín, D., & Martelletti, P. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2280221 · Cited by 9
“The four vaccines that have shown established efficacy and are the most widely used: BNT162b2 (from Pfizer-BioNTech) [88], mRNA-1273 (from Moderna) [89], ChAdOx1-S (from AstraZeneca) [90] and Ad26.”
MethodChen, K., Li, X., Feng, S., Li, Y., Jiang, T., Liu, Y., Guo, N., Zeng, X., Yao, H., Qiu, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114267 · Cited by 12
A multiobjective AI model for LNP engineering enhances tissue-selective mRNA delivery
Zhou, M., Xu, Y., Li, G., Chen, J., Savguira, M., Seto, B. Y., Gong, F., Thomson, T., Chen, J., Lu, R. X. Z., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03109-0 · Cited by 14
Sertić, Z., Lucijanić, M., Bašić‐Kinda, S., Seiwerth, R. S., Periša, V., Sertić, D., Coha, B., Pulanić, D., Perić, Z., Desnica, L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112892 · Cited by 7
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · doi:10.1101/2021.08.13.456316 · Cited by 8
“Previous mRNA vaccine clinical trials have demonstrated onset of protective efficacy after 146 the first dose and improved protection after the boost immunization [24, 25].”
BackgroundLuan, N., Wang, Y., Cao, H., Lin, K., & Liu, C. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27637 · Cited by 8
Peng, S., Zhang, Y., Zhao, X., Wang, Y., Zhang, Z., Zhang, X., Li, J., Zheng, H., Zhang, Y., Shi, H., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00536 · Cited by 9
Kuckertz, A., & Scheu, M. (2024) · Journal of Business Research · doi:10.1016/j.jbusres.2024.114570 · Cited by 12
Lin, Y., Chang, Y., Chou, W., & Yen, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147260 · Cited by 8
The status of COVID-19 vaccines in India: A review
Jha, D. K., Pranay, K., Samiksha, Kumar, A., & Yashvardhini, N. (2023) · Vacunas (English Edition) · doi:10.1016/j.vacun.2023.04.003 · Cited by 13
Rotundo, S., Serapide, F., Berardelli, L., Gullì, S. P., Mongiardi, S., Tassone, M. T., Trecarichi, E. M., & Russo, A. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11012-3 · Cited by 9
“…grappled with the unprecedented spread of SARS-CoV-2, the scientific community mobilized to develop effective vaccines to mitigate the impact of the virus and mRNA vaccines, emerged as groundbreaking innovations, demonstrating high efficacy in preventing severe illness and hospitalization [42].”
Ishmukhametov, A. A., Siniugina, A. A., Владимировна, Я. Н., Kuzubov, V. I., Анатольевич, З. К., Volok, V. P., Dodina, M., Gmyl, L. V., Коротина, Н. А., Theodorovich, R. D., et al. (2022) · medRxiv · doi:10.1101/2022.02.08.22270658 · Cited by 8
So, B., & Kwon, K. H. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2052467 · Cited by 11
“mRNA-1273) that were recently approved and recommended by the US Food and Drug Administration (FDA) and European Medicines Agency were 94–95% effective in preventing SARSCoV-2 infection [31,32].”
BackgroundHoffman, Y. S. G., Palgi, Y., Goodwin, R., Ben-Ezra, M., & Greenblatt-Kimron, L. (2021) · International Psychogeriatrics · doi:10.1017/s1041610221001071 · Cited by 9
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution
Li, L., Wei, Y., Han, Y., Yan, J., Li, X., Li, Z., Zhao, Y., Liang, H., & Wang, H. (2022) · Vaccines · doi:10.3390/vaccines10122035 · Cited by 8
Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient
Weinstock‐Guttman, B., & Jakimovski, D. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211022037 · Cited by 8
Kavikondala, S., Haeussler, K., Wang, X., Spellman, A., Bausch-Jurken, M. T., Sharma, P., Amiri, M., Krivelyova, A., Vats, S., Nassim, M., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00987-2 · Cited by 10
“Both mRNA-1273 and BNT162b2 administered in a 2dose series significantly reduced symptomatic infections and hospitalizations in immunocompetent populations evaluated in pivotal studies [4, 5].”
BackgroundKamamuta, A., Yuki, T., Takahashi, M., Kurihara, K., Shibata, H., Tanaka, K., & Hata, K. (2023) · Vaccines · doi:10.3390/vaccines11071151 · Cited by 9
“In contrast, the COVID-19 vaccine, including mRNA vaccines distributed in Japan (mRNA-1273 SARS-CoV-2 vaccine and BNT162b2 mRNA COVID-19 vaccine [44,45]), is known to cause Long-COVID-like symptoms, albeit at a low rate [11].”
BackgroundSARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies
Peluso, M. J., Dee, L., Taylor, J., Campbell, D. M., Ehm, A., Agosto-Rosario, M., Shao, S. J., Williams, M. C., Hoh, R., Rutishauser, R. L., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002690 · Cited by 8
Intratumoral cancer immunotherapy exploiting anti-viral immunity
Kadowaki, N. (2021) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.21023 · Cited by 8
Zürcher, K., Abela, I. A., Stange, M., Dupont, C., Mugglin, C., Egli, A., Trkola, A., Egger, M., & Fenner, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1005 · Cited by 8
“9) of vaccinated persons after at least seven days after two doses of the mRNA vaccine (3).”
BackgroundBarmpounakis, P., Demiris, N., Kontoyiannis, I., Pavlakis, G. N., & Sypsa, V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263977 · Cited by 10
Clothier, H. J., Shetty, A. N., Mesfin, Y. M., Mackie, M., Pearce, C. M., & Buttery, J. P. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.025 · Cited by 7
Potential of mRNA vaccines to become versatile cancer vaccines
Tsao, S. Y. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i8.663 · Cited by 9
Lee, C. M., Lee, E., Park, W. B., Choe, P. G., Song, K., Kim, E. S., & Park, S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e252 · Cited by 8
Should the SARS-CoV-2 vaccine be mandatory for nurses? An ethical debate
Osbourne, R. M., & Clark, S. J. (2021) · British Journal of Nursing · doi:10.12968/bjon.2021.30.2.116 · Cited by 9
Human Coronaviruses: Counteracting the Damage by Storm
Schoeman, D., & Fielding, B. C. (2021) · Viruses · doi:10.3390/v13081457 · Cited by 8
“Similarly, the Pfizer–BioNTech COVID-19 vaccines, BNT162b1 and BNT162b2, were able to induce antibody responses as well as the production of Th1 cytokines in most participants [226,235,236].”
MethodAdedoyin, O., Brijmohan, S., Lavine, R. T., & Lisung, F. G. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-246308 · Cited by 6
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13357 · Cited by 8
Shafrir, A., Amer, J., Hakimian, D., Milgrom, Y., Massarwa, M., Hazou, W., Imam, A., Khalaileh, A., & Safadi, R. (2022) · Hepatology Communications · doi:10.1002/hep4.1901 · Cited by 8
Chen, S., Li, J., Ma, X., et al. (2021) · Polymers · doi:10.3390/polym13213764 · Cited by 8
“The characteristics of high safety, high protection rates and easy production have reactivated the interest of researchers in RNA [1,2].”
BackgroundTailoring Alkyl Side Chains of Ionizable Amino-Polyesters for Enhanced In Vivo mRNA Delivery
Espinar, A. L., Mulder, L. M., Elkhashab, M., Khan, Z., Czarnocki‐Cieciura, M., Aburto, M. R., Vučen, S. R., & Kowalski, P. S. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00116 · Cited by 8
Chivese, T., Matizanadzo, J. T., Musa, O. A. H., et al. (2021) · medRxiv · doi:10.1101/2021.09.03.21263103 · Cited by 8
“Despite the rapid development of several efficacious and safe vaccines against COVID-19 (1, 2), access to the vaccines is limited due to enormous demand in the context of limited supply chains and complicated logistics needed for vaccine distribution (3).”
BackgroundLong Non-coding RNA Based Therapy for Cardiovascular Disease
Quinones, N. B., Belluomo, R., Juni, R. P., & Boon, R. A. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10686-z · Cited by 13
“LNPs have demonstrated success as delivery vehicles for therapeutic applications such as siRNA against transthyretin for cardiac amyloidosis treatment and COVID-19 mRNA vaccines [86–88].”
Conniff, A. S., Tur, J., Kohena, K., Zhang, M., Gibbons, J., & Heller, L. C. (2022) · Vaccines · doi:10.3390/vaccines10122037 · Cited by 11
“Clinical application of nonviral gene therapies significantly advanced with the development of the lipid nanoparticle—modified mRNA COVID vaccines [1,2].”
BackgroundPostvaccination COVID-19 among Healthcare Workers, Israel
Yousaf, Z., & Mushtaq, K. (2021) · Emerging infectious diseases · doi:10.3201/eid2706.210410 · Cited by 8
Nishikubo, M., Shimomura, Y., Maruoka, H., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18151 · Cited by 8
Gibson, V. P., Tahiri, H., Gilbert, C., Yang, C., Phan, Q. T., Banquy, X., & Hardy, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040563 · Cited by 8
Fisher, R., Tarnovsky, Y., Hirshoren, N., Kaufman, M., & Shavit, S. S. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-07869-2 · Cited by 8
“In December 2020, the mRNA Pfizer-and Moderna SARS-CoV-2 vaccines were authorized by the U.S. Food and Drug Administration (FDA) [1, 2].”
Rossi, M. A., Cena, T., Binala, J., Alessi, D., Scotti, L., & Faggiano, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-28129-7 · Cited by 11
Lombrea, A., Romanescu, M., Jianu, N., Andor, M., Suciu, M., Man, D. E., Danciu, C., Dehelean, C. A., & Buda, V. (2023) · Pharmaceuticals · doi:10.3390/ph16060853 · Cited by 8
“Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine (2020) [52] Logunov, D.”
BackgroundSun, J., Zheng, Q., Anzalone, A. J., Abraham, A. G., Olex, A. L., Zhang, Y., Mathew, J., Safdar, N., Haendel, M. A., Segev, D. L., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae019 · Cited by 10
Ferrari, D., Ambrosi, A., Resta, C. D., Tomaiuolo, R., Locatelli, M., & Banfi, G. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113293 · Cited by 9
“Its administration protocol has been based on a double dose approach which proved to be effective in preventing 95% of COVID-19 cases (Polack et al., 2020; Mulligan et al., 2020).”
Kuramochi, T., Gan, S. W., Ho, A. W. S., Wang, B., Kageji, N., Nambu, T., Iida, S., Okuda-Miura, M., Chia, W. S., Yeo, C. Y., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2040350 · Cited by 7
“Similarly, mRNA vaccines encoding the spike protein have been highly effective in eliciting protective antibody responses in vaccinated individuals.(4,5)”
BackgroundWang, T., Li, C., Li, H., & Li, Z. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057281 · Cited by 9
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.